Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome

Abdominal Obesity Metabolic Syndrome Clinical Trial

Official title:
A Randomized, Double-Blind, Placebo Controlled, Multicenter, 12-week Phase 3 Study to Evaluate Efficacy and Safety of ALS-L1023 Tablet in Patients With Abdominal Obesity of Metabolic Syndrome

Status Terminated

Clinical Trial Summary

The main objective of this study is to evaluate efficacy and safety of ALS-L1023 tablet in patients with abdominal obesity of metabolic syndrome.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Abdominal Obesity Metabolic Syndrome
Metabolic Syndrome X
Obesity
Obesity, Abdominal
Syndrome

Clinical Trial Details

NCT number	NCT01872182
Study type	Interventional
Source	Hanmi Pharmaceutical Company Limited
Contact
Status	Terminated
Phase	Phase 3
Start date	May 2013
Completion date	January 2015

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01887119` - Aldosterone Antagonism and Microvascular Function	Phase 4
Completed	`NCT02954588` - Effect of Pyridoxamine Supplementation on Vascular Function and Insulin Sensitivity	N/A
Completed	`NCT02283242` - Galantamine Effects in Patients With Metabolic Syndrome	Phase 4
Completed	`NCT03020186` - Effects of Green-MED Diet Via the Gut-fat-brain Axis	N/A
Completed	`NCT02353767` - Evaluation of Liver Fibrosis in HIV-infected Patients With Metabolic Syndrome	N/A
Recruiting	`NCT02001376` - A Health Promotion Project for Workers at National Taiwan University Hospital	N/A